Contributions
Abstract: 245
Type: Educational Session
Abstract Category: N/A
Introduction: Antibodies against the Myelin Oligodendrocyte Glycoprotein (MOG) are a biomarker for a subgroup of patients with CNS demyelinating diseases. MOG-antibodies were described in pediatric patients with ADEM and MS and in a subgroup of adult patients with clinical features of NMO but lacking the biomarker of anti-aquaporin 4 antibodies.
Aims: To describe two adult cases of a NMO like disease associated with anti-MOG antibodies.
Results: Both patients presented with the classical manifestation of myelitis and (bilateral) optic neuritis. The clinical course as well as diagnostics and treatment of both cases will be described and will be put into the context of larger case series. Clinical as well as biomarker indicators for a MOG associated CNS disease will be explained. Finally an update on treatment regimens will be presented.
Conclusions: Anti-MOG associated CNS demyelinating disease are more and more recognized as a distinct disease entity with characteristic clinical and imaging features. Recognition of this disease entity might be important regarding treatment decisions and prognosis.
Disclosure: Tobias Derfuss received speaker fees, research support, travel support, and/or served on Advisory Boards and/or steering committees of Novartis Pharma, Merck Serono, Biogen, Teva, Bayer-Schering, GeNeuro, Mitsubishi Pharma, MedDay, Roche, Genzyme.
Abstract: 245
Type: Educational Session
Abstract Category: N/A
Introduction: Antibodies against the Myelin Oligodendrocyte Glycoprotein (MOG) are a biomarker for a subgroup of patients with CNS demyelinating diseases. MOG-antibodies were described in pediatric patients with ADEM and MS and in a subgroup of adult patients with clinical features of NMO but lacking the biomarker of anti-aquaporin 4 antibodies.
Aims: To describe two adult cases of a NMO like disease associated with anti-MOG antibodies.
Results: Both patients presented with the classical manifestation of myelitis and (bilateral) optic neuritis. The clinical course as well as diagnostics and treatment of both cases will be described and will be put into the context of larger case series. Clinical as well as biomarker indicators for a MOG associated CNS disease will be explained. Finally an update on treatment regimens will be presented.
Conclusions: Anti-MOG associated CNS demyelinating disease are more and more recognized as a distinct disease entity with characteristic clinical and imaging features. Recognition of this disease entity might be important regarding treatment decisions and prognosis.
Disclosure: Tobias Derfuss received speaker fees, research support, travel support, and/or served on Advisory Boards and/or steering committees of Novartis Pharma, Merck Serono, Biogen, Teva, Bayer-Schering, GeNeuro, Mitsubishi Pharma, MedDay, Roche, Genzyme.